Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total neoadjuvant therapy for early-stage low rectal cancer
ACTRN12625000583448Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Jun 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, capecitabine, oxaliplatin and folinic acid in rectal adenocarcinoma and rectal cancer, sponsored by Royal Adelaide Hospital. Primary endpoint: Complete clinical response rate. Started Jun 2025; status: recruiting.
02
Drugs
fluorouracilcapecitabineoxaliplatinfolinic acid
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ACTRN12625000583448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000583448.